Drugs / DS-5141b
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02667483 | Oct 2015 → Oct 2020 | Duchenne muscular dystrophy | Daiichi Sankyo | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04433234 | Jun 2020 → Jan 2027 expected | Duchenne muscular dystrophy | Daiichi Sankyo | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2017-04-24 | Daiichi Sankyo | Regulatory Daiichi Sankyo Announces Designation of Duchenne Muscular Dystrophy Treatment DS-5141 under “SAKIGAKE Designation System” daiichisankyo.com ↗ |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2017-04-24 | Daiichi Sankyo | Daiichi Sankyo Announces Designation of Duchenne Muscular Dystrophy Treatment DS-5141 under “SAKIGAKE Designation System” daiichisankyo.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DS-5141b | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04433234 ↗ |
| Route | Subcutaneous | “DS-5141b, Subcutaneous injection” NCT02667483 ↗ |